Author

E. Kalaitzaki

Observed names: E Kalaitzaki, Eletheria Kalaitzaki, Kalaitzaki, E

Institutions: Royal Marsden NHS Foundation Trust, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology

Observed institutions: Guy's Hospital, NHS Lothian, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Velindre NHS Trust, Leeds Teaching Hospitals NHS Trust, Royal Devon & Exeter NHS Foundation Trust, University Hospitals of North Midlands NHS Trust, Bolton NHS Foundation Trust, University of Manchester, Kings Health Partners, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Medical Research Council

OpenAlex ID: A5019485656

Two‐stage method to remove population‐ and individual‐level outliers from longitudinal data in a primary care database

2011 · C. Welch, I. Petersen, et al. · Pharmacoepidemiology and Drug Safety · 27

Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)—first results from PathIES

2015 · V. Speirs, G. Viale, et al. · Annals of Oncology · 13

Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: a single-centre experience

2017 · C. Kingston, H. Kayhanian, et al. · European Journal of Cancer · 5

Abstract PD5-06: Effects of perioperative lapatinib in early HER2+ breast cancer - The UK EPHOS-B trial (CRUK/08/002)

2016 · N Bundred, D Cameron, et al. · Cancer Research · 3

Prognostic and Predictive Value of IHC4 and ERB1 in the Intergroup Exemestane Study (IES) - On Behalf of the Pathies Investigators

2013 · G. Viale, V. Speirs, et al. · Annals of Oncology · 3

Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety run-in

2019 · M. Davidson, S. Mansukhani, et al. · Annals of Oncology · 1

KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial

2016 · F. Sclafani, I. Chau, et al. · Annals of Oncology · 1

Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups

2011 · Roger A’Hern, Johann DeBono, et al. · Trials · 1

MONITORING RARE EVENTS IN A SINGLE ARM NON-INFERIORITY TRIAL (111; CRUK/09/011) (vol 9, pg 539, 2012)

2014 · Kalaitzaki, E, A'Hern, R, et al. · UCL Discovery (University College London)

Abstract P6-06-03: Differing patterns of treatment effect in a trial assessing sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT)

2013 · R A'Hern, C Gillett, et al. · Cancer Research

Works count: 10

Citation count: 54

H-index: 3

I10-index: 2